J.‐C. Wu

Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen‐negative chronic hepatitis B patients in Taiwan

F. Chang, T. Huo, T.‐T. Chang, 2003, Journal of viral hepatitis.

Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma.

C. Chi, W. Lui, S. Chiang, 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter

F. Chang, T. Huo, J.‐C. Wu, 2006, Alimentary pharmacology & therapeutics.

The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nationwide, multicentre study evaluated by cancer stage

Hsuan‐Shu Lee, J. Sheu, T. Huo, 2005, Alimentary pharmacology & therapeutics.

Long‐term evaluation of recombinant interferon α2b in the treatment of patients with hepatitis B e antigen‐negative chronic hepatitis B in Taiwan

S. Lee, J.‐C. Wu, Y.‐J. Wang, 2001, Journal of viral hepatitis.

Is there an ideal prognostic model for hepatocellular carcinoma?

T. Huo, S. Lee, J.‐C. Wu, 2005, Gut.

Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D

K. Choo, T. Huo, S. Lee, 1995, The Lancet.

A randomized controlled clinical trial of recombinant interferon α‐2b in the treatment of acute post‐transfusion hepatitis C: A preliminary report

K. Lo, S. Lee, S. Hwang, 1993 .

Association of core promoter/precore mutations and viral load in e antigen‐negative chronic hepatitis B patients

T. Huo, I. Sheen, S. Lee, 2006, Journal of viral hepatitis.

Do baseline ALT levels predict complications of chronic hepatitis B?

T. Huo, S. Lee, J.‐C. Wu, 2006, Gut.